Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 8/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060253 | 0.86 | ACE (0.59) | RAB9ANPC1ACEMMELMNA | |
| SCHEMBL19885992 | 0.85 | NPC1 (0.54) | RAB9ANPC1ACEMME | |
| SCHEMBL11964372 | 0.84 | CYP3A4 (0.65) | RAB9ANPC1SMN1; SMN2ACEEPHX2 | |
| SCHEMBL15222315 | 0.81 | MME (0.67) | ACEMMECPA1ACE2 | |
| SCHEMBL22515871 | 0.80 | ACE (0.53) | RAB9ANPC1ACE | |
| SCHEMBL19888905 | 0.80 | ACE (0.53) | RAB9ANPC1ACE | |
| SCHEMBL15222230 | 0.80 | MMP2 (0.58) | ACEALDH1A1MMECPA1ACE2 | |
| SCHEMBL21287068 | 0.79 | ACE (0.45) | RAB9ANPC1ACE | |
| SCHEMBL15222234 | 0.79 | ALDH1A1 (0.56) | ACEALDH1A1MMECPA1ACE2 | |
| SCHEMBL15222314 | 0.78 | MME (0.71) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | RAB9A 1348/4885NPC1 2490/4885SMN1; SMN2 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.